Page last updated: 2024-08-24

capecitabine and veliparib

capecitabine has been researched along with veliparib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Czito, BG; DeLuca, A; Deming, DA; Dudley, MW; He, L; Holen, KD; Jameson, GS; Komarnitsky, P; Michael, M; Mittapalli, RK; Mulcahy, MF; Munasinghe, W; Ngan, SY; Vaghefi, H; Zalcberg, JR	1

Trials

1 trial(s) available for capecitabine and veliparib

Article	Year
Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study. The lancet. Gastroenterology & hepatology, 2017, Volume: 2, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Benzimidazoles; Capecitabine; Chemoradiotherapy; Diarrhea; Fatigue; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Poly(ADP-ribose) Polymerase Inhibitors; Rectal Neoplasms	2017

Article

Year

Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.

The lancet. Gastroenterology & hepatology, 2017, Volume: 2, Issue:6

Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Benzimidazoles; Capecitabine; Chemoradiotherapy; Diarrhea; Fatigue; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Poly(ADP-ribose) Polymerase Inhibitors; Rectal Neoplasms

2017